Abatacept is under clinical development by Bristol-Myers Squibb and currently in Phase III for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis). According to GlobalData, Phase III drugs for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Abatacept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Abatacept (Orencia/ Ohrencia) is a soluble fusion protein produced by recombinant DNA technology in Chinese hamster ovary cells. It is formulated as an solution for subcutaneous route and powder for concentrate solution for intravenous route of administration. It is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis, for reducing signs and symptoms in pediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis. It may be used as monotherapy or concomitantly with methotrexate (MTX), indicated for reducing signs and symptoms of juvenile rheumatoid arthritis in pediatric patients 6 years of age and older who have had an inadequate response to one or more DMARDs, such as MTX. Orencia in combination with methotrexate (MTX), for the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis (RA) not previously treated with MTX, indicated as alone or in combination with methotrexate for the treatment of active Psoriatic Arthritis (PsA) in adult patients for whom the response to previous disease-modifying antirheumatic drug (DMARD) therapy, including methotrexate, has been inadequate, and additional systemic therapy for psoriatic skin lesions is not required.
Abatacept is under development for the treatment of cytopenia, idiopathic inflammatory myopathy, polymyalgia rheumatica, interstitial lung diseases, Wegener's granulomatosis, immunoglobulin G4-related disease (IgG4-RD), graft versus host disease, COVID-19, myocarditis. It is administered through intravenous and subcutaneous routes. It acts by targeting CTLA 4.
It was also under development for the treatment of dermatomyositis, polymyositis, vitiligo, nephrotic syndrome including focal segmental glomerulosclerosis, uveitis, primary Sjogren's syndrome, psoriasis, alopecia areata, ulcerative colitis, Crohn's disease, sarcoidosis, giant cell arteritis, Takayasu arteritis, relapsing-remitting multiple sclerosis, chronic urticarial, untreated rheumatoid arthritis (intravenous), lupus nephritis (subcutaneous, intravenous), myasthenia gravis, systemic sclerosis, systemic lupus erythematosus and immune-mediated necrotizing myopathy
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
For a complete picture of Abatacept’s drug-specific PTSR and LoA scores, buy the report here.